A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Assess the Efficacy, Safety, and Tolerability of SR419 in Patients with Postherpetic Neuralgia (PHN).
- Year: 2022
- Type: Pharmaceutical - Pain
- Phase: II
- Indication: Neuropathic Pain, Postherpetic Neuralgia